A new initiative between two Houston organizations is dedicating resources to Black entrepreneurs. Photo via houston.impacthub.net

Impact Hub Houston has partnered with the Black Marketing Initiative to offer a new training, mentoring, and networking program for local black entrepreneurs in honor of Black History Month.

Dubbed MarketBlack, the program will provide participants with 7 weeks of workshops and interactive training modules designed to help them create successful business plans and foster growth through practical lessons from educators and fellow entrepreneurs, according to a statement from Innovation Hub Houston.

The idea was born in June of 2020 when BMI conducted its Community Checkup campaign to assess the vitality of minority-owned small businesses in Houston amid the pandemic. The campaign surveyed 226 mostly Black-owned businesses, according to Impact Hub Houston's website. Nearly half of those surveyed reported that they needed business and marketing support.

The program will aim to provide participating entrepreneurs with the skills to keep their businesses alive through the remainder of the pandemic and beyond.

"The Black Marketing Initiative is not just about being Black — it is also about the belief that community can positively impact us all," says Action Jackson, a leader and organizer of MarketBlack. "Successful Black entrepreneurs are good for business. Good for community. Good for everybody."

The program is open to Houston-based small businesses that make less than $50,000 a year, are less than 5 years old, and are majority Black-owned. The owner must be at least 18 years old. Interested business owners can apply here.

According to ImpactHub, the majority of businesses that have participated thus far have not had a business plan and make less than $25,000 in annual revenue. Participants have ranged in age from 20 to 47, are split about evenly between male and female, and have all been Black with one participant also claiming American Indian or Alaskan Native Heritage.

Impact Hub Houston is sponsoring and raising funds for the program, as well as opening its network and community to participants. According to the nonprofit's website, a donation of $100 can support one entrepreneur through the program.

Houston-based Sankofa Research Institute is providing BMI with progress and outcomes to give the organization a snapshot of Houston's Black business community and determine the efficacy of the program.

Other partners and participants in MarketBlack include Action One Media, Marcus Bowers of Marcus Bowers TV and She's Happy Hair, Choose to Do Inc, Emergent Business Solutions, and South Union CDC of the Sunnyside Energy Project. These organizations and other local business owners act as panelists, instructors, and even financial partners to the participants.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”